Responses to treatment by PD-1/PD-L1 drugs were searched for clinical trials for other six cancers, including renal [2], head-and-neck, gastric or gastro-esophageal, hepatocellular carcinoma, melanoma [3], and urothelial (Supplementary Table S1). This evidence concerns the gene CD274 and cancer.